dis3 Antibody

What is DIS3 and what cellular functions does it serve?

DIS3 (also known as RRP44) functions as a catalytic subunit of the exosome complex with both exonucleolytic and endonucleolytic activities. It plays critical roles in RNA metabolism by degrading unstable mRNAs containing AU-rich elements in their untranslated regions . DIS3 is a 958 amino acid protein widely expressed throughout tissues, with highest expression observed in testis, and contains a PINc domain critical for its exoribonuclease activity . It localizes in both the cytoplasm and nucleus, where it participates in the processing of 7S pre-RNA into mature nuclear complexes, ensuring proper mitotic progression . DIS3 has emerged as a significant player in human disease, with dysregulation implicated in colon cancer and frequent mutations observed in multiple myeloma .

What types of DIS3 antibodies are available for research applications?

Commercial DIS3 antibodies are available in several formats, including monoclonal and polyclonal variants. For example, DIS3 Antibody (H-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects DIS3 protein from mouse, rat, and human samples . Rabbit polyclonal antibodies against DIS3 are also available, such as those targeting the N-terminal region (amino acids 1-50) of human DIS3 . These antibodies are typically available in both non-conjugated forms and conjugated variants including:

• Horseradish peroxidase (HRP) conjugates for enhanced chemiluminescent detection

• Fluorescent conjugates (PE, FITC, Alexa Fluor variants) for flow cytometry and fluorescence microscopy

• Agarose conjugates for immunoprecipitation applications

For optimal results when using DIS3 antibodies, dilution optimization should be performed for each specific application and experimental system. Begin with the manufacturer's recommended dilution ranges:

• Western blotting: Typically 1:100-1:1000 dilution range

• Immunofluorescence: Usually more dilute, around 1:50-1:500

• Immunoprecipitation: Often requires higher concentrations, 2-5 μg per sample

• ELISA: Variable based on kit specifications, generally 1:100-1:2000

Perform a dilution series experiment comparing signal-to-noise ratios across multiple concentrations. For western blotting, consider implementing a positive control (cell line known to express DIS3 highly, such as testicular tissue extracts) and negative control (knockdown or knockout samples if available). When developing optimal protocols, be mindful that antibody performance may vary between lots and storage conditions can impact sensitivity and specificity.

How can I validate DIS3 antibody specificity for my experimental system?

Validating DIS3 antibody specificity is crucial for generating reliable research data. A comprehensive validation approach should include:

• Genetic knockdown/knockout controls: Compare antibody signal in wild-type samples versus DIS3 siRNA/shRNA knockdown or CRISPR/Cas9 knockout samples to confirm specificity.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application to samples; specific signals should be significantly reduced or eliminated.

• Multiple antibody comparison: Use antibodies targeting different epitopes of DIS3 and compare detection patterns.

• Recombinant protein expression: Express tagged recombinant DIS3 protein in a system with low endogenous expression and verify co-localization of tag and antibody signals.

• Mass spectrometry verification: Following immunoprecipitation with the DIS3 antibody, perform mass spectrometry to confirm the presence of DIS3 peptides in the isolated complex.

For PAR-CLIP experiments specifically, as performed in studies examining DIS3's role in RNA metabolism, cross-validation can be achieved by comparing sequenced reads with untemplated nucleotide signatures, as authentic DIS3 interactions often show characteristic T-C transitions (27-32% of reads) .

How can I design effective experiments to study the role of DIS3 in RNA metabolism using antibody-based approaches?

When investigating DIS3's role in RNA metabolism, consider implementing a multi-faceted experimental design:

• Ribonucleoprotein immunoprecipitation followed by sequencing (RIP-seq):

  • Crosslink RNA-protein complexes using formaldehyde or UV

  • Immunoprecipitate with DIS3 antibody under high-salt conditions (to isolate DIS3 separately from the exosome complex)

  • Extract and sequence associated RNAs

  • Compare with appropriate controls (IgG IP, input samples)

• Photoactivatable Ribonucleoside-Enhanced Cross-Linking and Immunoprecipitation (PAR-CLIP):

  • Incorporate 4-thiouridine into cellular RNAs

  • UV crosslink at 365 nm

  • Immunoprecipitate with DIS3 antibody

  • Look for characteristic T-C transitions in sequenced reads (27-32% of reads indicate high specificity)

  • Analyze without strict focus on T-C transitions for higher coverage of DIS3-bound RNAs

• Antibody-mediated depletion coupled with RNA-seq:

  • Generate cell lines expressing mutant DIS3 (RNB domain, PIN domain, or double mutants)

  • Perform RNA-seq to identify accumulated transcripts

  • Complement with PAR-CLIP to differentiate direct versus indirect targets

  • Validate findings using qPCR for selected targets

Notable findings using these approaches revealed that DIS3 dysfunction leads to global transcriptome alterations, with pervasive transcription products increasing ∼2.5-fold and covering ∼70% of the genome .

What controls should be included when using DIS3 antibodies to study its role in DNA damage and genome integrity?

When investigating DIS3's role in DNA damage and genome integrity, implement these essential controls:

• Antibody specificity controls:

  • Include isotype control antibodies

  • Perform siRNA/shRNA-mediated DIS3 knockdown to confirm signal specificity

  • Include wild-type and DIS3-depleted cells in all experiments

• DNA:RNA hybrid detection controls:

  • When using S9.6 antibody to detect DNA:RNA hybrids, include RNase H treatment (should eliminate signal)

  • Include RNase III treatment as a negative control (should not affect DNA:RNA hybrid signal)

  • Use dot blot quantification alongside immunofluorescence for cross-validation

• DNA damage response validation:

  • For comet assays measuring DNA breaks, include RNase H treatment to establish causality between DNA:RNA hybrids and DNA damage

  • Include γ-irradiated cells as positive controls for DDR foci formation

  • Perform ChIP-qPCR at known DSB sites using both DIS3 antibodies and DDR factor antibodies (e.g., RAD51)

• Functional rescue experiments:

  • Complement DIS3-depleted cells with wild-type or catalytically inactive DIS3 variants

  • Measure restoration of normal phenotypes (reduced DNA:RNA hybrids, decreased DNA damage)

Recent research using these controls has demonstrated that loss of DIS3 leads to DNA:RNA hybrid accumulation throughout the genome, resulting in increased DNA double-strand breaks and impaired recruitment of repair factors like RAD51 .

Why might I observe inconsistent DIS3 detection in western blotting experiments?

Inconsistent DIS3 detection in western blotting can stem from multiple factors:

• Alternative splicing considerations: DIS3 exists in multiple isoforms due to alternative splicing , which may affect epitope availability and antibody recognition. Ensure your antibody targets a conserved region across relevant isoforms.

• Sample preparation issues:

  • Inadequate cell lysis: DIS3 has both nuclear and cytoplasmic localization; ensure your lysis buffer can extract both pools

  • Protein degradation: Include appropriate protease inhibitors freshly in all buffers

  • Denaturing conditions: Some epitopes may be sensitive to reducing agents or high temperatures

• Technical parameters:

  • Transfer efficiency for large proteins: DIS3 is a large protein (958 amino acids), requiring optimized transfer conditions

  • Blocking reagents: Milk may contain phosphatases that affect detection of phospho-regulated proteins; consider BSA as an alternative

  • Membrane type: PVDF membranes often provide better retention of large proteins than nitrocellulose

• Antibody-specific factors:

  • Lot-to-lot variability: Request information about lot-specific validation

  • Storage conditions: Avoid repeated freeze-thaw cycles and confirm proper long-term storage

  • Dilution optimization: Titrate antibody concentration specifically for your cell type

If inconsistencies persist, consider testing the antibody on cells with manipulated DIS3 expression (overexpression, knockdown) to establish a clear detection range and pattern.

How can I optimize immunoprecipitation protocols for studying DIS3-associated RNA or protein complexes?

Optimizing immunoprecipitation of DIS3 complexes requires careful consideration of protein-protein and protein-RNA interactions:

• Lysis buffer optimization:

  • For protein-protein interactions: Use buffers containing 150-300 mM NaCl, 0.5-1% NP-40 or Triton X-100, with protease and phosphatase inhibitors

  • For exosome core separation: Implement high-salt conditions (>500 mM NaCl) to specifically isolate DIS3 apart from the exosome complex

  • For RNA-associated complexes: Include RNase inhibitors (RNasin, SUPERase-In)

• Crosslinking considerations:

  • For transient interactions: Use DSP or formaldehyde (0.1-1%) for protein-protein crosslinking

  • For RNA-protein complexes: UV crosslinking (254 nm) or incorporation of 4-thiouridine followed by 365 nm crosslinking

• IP protocol refinements:

  • Pre-clear lysates with appropriate beads to reduce background

  • Optimize antibody-to-sample ratio (typically 2-5 μg antibody per 500 μg protein lysate)

  • Consider using conjugated antibody-bead complexes for direct IP

  • Extend incubation time (4-16 hours) at 4°C with gentle rotation

• Washing stringency balance:

  • For core protein interactions: More stringent washes (higher salt, detergent)

  • For RNA-associated complexes: Less stringent conditions to preserve interactions

  • Consider including graduated washing steps with decreasing stringency

In PAR-CLIP experiments with DIS3, researchers successfully optimized protocols using high-salt conditions that disrupted DIS3's interaction with the exosome core, allowing for specific isolation of DIS3-bound RNAs .

How can I differentiate between direct and indirect targets of DIS3 in transcriptome analyses?

Distinguishing direct from indirect DIS3 targets requires integrating multiple methodological approaches:

• Combine PAR-CLIP with RNA-seq:

  • PAR-CLIP identifies direct RNA binding targets (look for T-C transitions as hallmarks)

  • RNA-seq in DIS3 mutant/knocked-down cells identifies accumulated transcripts

  • Overlap between these datasets suggests direct targets

  • Transcripts that change in RNA-seq but lack PAR-CLIP signal likely represent indirect effects

• Catalytic mutant approach:

  • Generate cells expressing catalytically inactive DIS3 (RNB and/or PIN domain mutants)

  • Compare transcriptome changes between different mutants

  • RNAs accumulating in exonuclease-deficient but not endonuclease-deficient cells represent substrate-specific impacts

• Kinetic analyses:

  • Perform time-course experiments after DIS3 depletion/inhibition

  • Early-responding transcripts (0-4 hours) are more likely direct targets

  • Late-responding changes (12-24+ hours) often represent secondary effects

• Correlation analysis:

  • PROMPTs (Promoter Upstream Transcripts) accumulate robustly in DIS3 mutants but show no correlation with neighboring gene expression (Spearman correlation coefficient = 0.0431, p-value = 0.144)

  • This suggests PROMPTs are direct targets without regulatory impact on adjacent genes

Research using these approaches has revealed that while DIS3 dysfunction affects ~50% of protein-coding genes, many represent secondary effects from accumulation of noncoding RNA species .

What are the key considerations when studying DIS3's role in DNA:RNA hybrid regulation using antibody-based approaches?

When investigating DIS3's involvement in DNA:RNA hybrid regulation, consider these critical factors:

• S9.6 antibody validation:

  • The S9.6 antibody is the standard tool for detecting DNA:RNA hybrids but requires rigorous controls

  • Include RNase H treatment controls (should eliminate signal)

  • Include RNase III treatment (should not affect DNA:RNA hybrid signal)

  • Use dot blot quantification alongside immunofluorescence for cross-validation

• Cell cycle considerations:

  • DNA:RNA hybrids accumulate differently across cell cycle phases

  • Consider synchronizing cells or using cell cycle markers in flow cytometry/immunofluorescence

  • Analyze whether DIS3 depletion affects specific cell cycle phases differently

• Genomic region specificity:

  • Implement DRIP-seq (DNA:RNA Immunoprecipitation followed by sequencing) to map hybrid locations

  • Perform ChIP-qPCR for specific genomic regions where DNA:RNA hybrids tend to form:

    • rDNA loci

    • Telomeres

    • Highly transcribed genes

    • Repetitive elements

• Functional impact assessment:

  • Correlate DNA:RNA hybrid accumulation with DNA damage markers (γH2AX, 53BP1 foci)

  • Use comet assays with/without RNase H treatment to establish causality

  • Assess recruitment of DNA repair factors (RAD51, BRCA1/2) to damage sites via ChIP-qPCR

Research using these approaches has demonstrated that DIS3 knockdown increases DNA:RNA hybrids throughout the genome, leading to DNA damage that can be rescued by RNase H treatment, confirming the hybrids' causal role in genomic instability .

How should I interpret complex transcriptome data from DIS3 mutant studies in the context of direct versus indirect effects?

Interpreting transcriptome data from DIS3 mutant studies requires nuanced analytical approaches:

• Categorize transcript classes affected by DIS3 dysfunction:

  • PROMPTs: Represent 0.88% of mapped reads in PIN+RNB mutants (vs. 0.16% in wild-type)

  • Novel unannotated transcripts: Increase from 4% to 9% in DIS3 double mutants

  • snoRNA precursors: Strongly accumulate in DIS3 mutants

  • Protein-coding mRNAs: ~50% show expression changes

• Apply genome coverage analysis:

  • The fraction of the genome covered by transcription increases from 43% (SD 1.99%) in WT to 74% (SD 2.52%) in DIS3 double mutants

  • This indicates DIS3's crucial role in limiting pervasive transcription

• Consider post-transcriptional regulatory networks:

  • Changes in noncoding RNA populations (PROMPTs, eRNAs) may impact mRNA stability indirectly

  • Accumulation of aberrant RNAs may sequester RNA binding proteins from their normal targets

• Analyze specific transcript relationships:

  • No correlation between PROMPT accumulation and neighboring gene expression (Spearman coefficient = 0.0431, p-value = 0.144)

  • For 85 enhancers with detectable eRNAs that accumulated in DIS3 mutants:

    • 80% of neighboring genes showed minimal expression changes

    • Only 3.5% showed increased expression

    • 16.5% showed decreased expression

This complex data suggests that while DIS3 directly degrades many noncoding RNAs, the altered transcriptome landscape creates widespread secondary effects on protein-coding gene expression through mechanisms that remain to be fully elucidated.

How can I apply DIS3 antibodies to study its role in cancer biology, particularly in multiple myeloma?

DIS3 mutations are frequently observed in multiple myeloma, suggesting important functions in cancer biology. To investigate these roles:

• Patient sample characterization:

  • Use DIS3 antibodies for immunohistochemistry on patient tissue microarrays

  • Correlate DIS3 expression/localization with clinical parameters and outcomes

  • Analyze both protein levels and mutation status through combined approaches

• Cancer-specific pathways:

  • Investigate DNA damage levels in DIS3-mutant cancer cells using γH2AX immunofluorescence

  • Assess genomic instability through cytogenetic analyses and correlation with DIS3 status

  • Examine DNA:RNA hybrid accumulation in patient-derived samples using S9.6 antibody

• Therapeutic vulnerability assessment:

  • Screen DIS3-mutant versus wild-type cells for differential drug sensitivity

  • Test whether RNase H1 overexpression can rescue phenotypes associated with DIS3 mutation

  • Investigate synthetic lethality approaches targeting cells with compromised DIS3 function

• Mechanistic investigations:

  • Characterize how DIS3 mutations affect RAD51 recruitment to DNA damage sites

  • Determine whether specific RNA classes accumulate in DIS3-mutant patient samples

  • Assess impact on DNA damage response pathway activation in patient-derived cells

Recent studies have established that loss of DIS3 function compromises genome integrity in multiple myeloma by impairing homologous recombination repair, potentially explaining the high frequency of DIS3 mutations in this cancer type .

What are the considerations for developing CHIP-seq protocols with DIS3 antibodies?

While DIS3 is primarily known as an RNA-processing enzyme rather than a DNA-binding protein, recent evidence suggests it may associate with chromatin in specific contexts. For developing DIS3 ChIP-seq protocols:

• Antibody selection and validation:

  • Test multiple DIS3 antibodies in pilot ChIP-qPCR experiments

  • Verify specificity using DIS3 knockdown/knockout controls

  • Consider epitope accessibility in the context of chromatin-associated complexes

• Crosslinking optimization:

  • Test different formaldehyde concentrations (0.5-2%)

  • Evaluate dual crosslinking approaches (e.g., DSG followed by formaldehyde)

  • Consider native ChIP approaches if crosslinking efficiency is low

• Experimental design considerations:

  • Include appropriate controls (IgG, input samples)

  • Use spike-in chromatin for normalization between samples

  • Consider cell cycle synchronization as DIS3 chromatin association may be cell cycle-dependent

• Data analysis approaches:

  • Compare DIS3 binding with RNA polymerase II occupancy

  • Analyze overlap with regions prone to DNA:RNA hybrid formation

  • Correlate with sites of DNA damage or repair factor recruitment

• Functional validation:

  • Perform DIS3 ChIP-qPCR at sites where DNA:RNA hybrids form

  • Test whether DIS3 recruitment changes upon transcription inhibition or DNA damage

  • Assess whether catalytically inactive DIS3 shows altered chromatin association

This emerging research direction may help elucidate whether DIS3 plays direct roles at the chromatin level or primarily acts post-transcriptionally on RNA substrates.

How can I design experiments to determine if specific DIS3 mutations affect antibody recognition and experimental outcomes?

DIS3 mutations are frequent in multiple myeloma and may affect antibody recognition, potentially confounding experimental interpretation:

• Epitope mapping analysis:

  • Determine the exact epitope recognized by your DIS3 antibody

  • Cross-reference with known mutation hotspots in cancer databases

  • Generate cell lines expressing specific DIS3 mutations to test antibody recognition

• Multiple antibody comparison strategy:

  • Use antibodies targeting different regions of DIS3 protein

  • Compare detection patterns in samples with known mutations

  • Establish a panel of validated antibodies for different experimental scenarios

• Recombinant protein controls:

  • Express wild-type and mutant DIS3 proteins with epitope tags

  • Compare detection by DIS3 antibodies versus tag antibodies

  • Create standard curves for quantitative applications

• Functional domain considerations:

  • RNB domain mutations affect exoribonuclease activity but may not affect antibody binding

  • PIN domain mutations impact endonuclease function

  • Double mutants (PIN+RNB) show the most profound phenotypes in transcriptome studies

• Alternative detection strategies:

  • Consider CRISPR knock-in of tags (FLAG, HA) to endogenous DIS3

  • Implement proximity ligation assays to verify protein-protein interactions

  • Use mass spectrometry to confirm antibody target specificity in immunoprecipitates

Through careful antibody validation and experimental design, researchers can ensure reliable detection of both wild-type and mutant DIS3 proteins, critical for accurate interpretation of results in cancer biology studies.